Turning Genes into Medicine: Reimagining Our Health Care System

Recent scientific advances in the field of gene therapy have raised the prospect of a new approach to treating rare, chronic and inherited diseases.

Are industry stakeholders prepared for how these breakthroughs may impact the health care market? How will payers cover therapies that are one-time treatments? How should regulators and policymakers approach these new treatment options to ensure affordability, access and incentives for further innovation?

The Hill convened government leaders, health industry representatives, researchers, patient advocates, and other thought-leaders for a discussion about the impact of medical breakthroughs on the American health ecosystem and patients.


  • Congresswoman Suzan DelBene (D-WA), Member, Rare Disease Congressional Caucus
  • Congressman Patrick Meehan (R-PA), Member, House Ways and Means Committee
  • Paul Brayshaw, Hemophilia Patient Advocate
  • Gregory Daniel, Ph.D., Deputy Director, Duke-Margolis Center for Health Policy
  • Tom DiLenge, President, Advocacy, Law & Public Policy Division, Biotechnology Innovation Organization
  • Jeff Marrazzo, CEO, Spark Therapeutics
  • Steve Miller, M.D., Senior Vice President and Chief Medical Officer, Express Scripts


  • Bob Cusack, Editor-in-Chief, The Hill
  • Kim Dixon, Policy Editor, The Hill

Sponsored By: